Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for seladelpar (Lyvdelzi) for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.